THE INFORMATION BELOW MARKED * AND [ ] HAS BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTIONS HAVE BEEN
SEPARATELY FILED WITH THE COMMISSION.
LICENSE AGREEMENT
DATED DECEMBER 31, 1996
BETWEEN
PROGENITOR, INC.
AND
AMGEN INC.
TABLE OF CONTENTS
SECTION PAGE
ARTICLE 1 - DEFINITIONS
1.1 Active Component. . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Affiliate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.3 Agreement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.4 Combined Product. . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.5 Confidential Information. . . . . . . . . . . . . . . . . . . . . . 2
1.6 Controls/Controlled . . . . . . . . . . . . . . . . . . . . . . . . 2
1.7 Default . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.8 Effective Date. . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.9 FDA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.10 Field of Use. . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.11 First Commercial Sale . . . . . . . . . . . . . . . . . . . . . . . 2
1.12 Force Majeure . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.13 GAAP. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.14 IND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.15 Licensed Patents. . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.16 Licensed Product(s) . . . . . . . . . . . . . . . . . . . . . . . . 3
1.17 Net Sales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.18 New Product . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.19 Party . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.20 Patent Right. . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.21 Person. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.22 Phase III Licensing Trial . . . . . . . . . . . . . . . . . . . . . 3
1.23 Product . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.24 Progenitor Ancillary Patents. . . . . . . . . . . . . . . . . . . . 4
1.25 Progenitor Receptor Patents . . . . . . . . . . . . . . . . . . . . 4
1.26 Royalties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.27 Third Party . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.28 Third Party Royalties . . . . . . . . . . . . . . . . . . . . . . . 4
ARTICLE 2 - REPRESENTATIONS AND WARRANTIES
2.1 Representations and Warranties of Progenitor. . . . . . . . . . . . 4
2.2 Representations and Warranties of Amgen . . . . . . . . . . . . . . 5
ARTICLE 3 - LICENSE GRANT
3.1 Technology Ownership. . . . . . . . . . . . . . . . . . . . . . . . 5
3.2 License Grant . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
3.3 Retained Rights . . . . . . . . . . . . . . . . . . . . . . . . . . 6
i
ARTICLE 4 - DEVELOPMENT AND COMMERCIALIZATION
4.1 Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
4.2 Commercialization . . . . . . . . . . . . . . . . . . . . . . . . . 7
4.3 Annual Statement. . . . . . . . . . . . . . . . . . . . . . . . . . 7
ARTICLE 5 - CONSIDERATION
5.1 License Fee and Equity Purchases. . . . . . . . . . . . . . . . . . 7
5.2 License Maintenance Fee . . . . . . . . . . . . . . . . . . . . . . 7
5.3 Milestones. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
5.4 Royalties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
5.5 Credits Against Royalties and Milestone Payments. . . . . . . . . . 10
5.6 Payment of Royalties. . . . . . . . . . . . . . . . . . . . . . . . 10
ARTICLE 6 - RECORDS; AUDIT
6.1 Record Retention. . . . . . . . . . . . . . . . . . . . . . . . . . 11
6.2 Royalty Audit . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
6.3 Survival. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
ARTICLE 7 - PATENTS
7.1 Patent Prosecution. . . . . . . . . . . . . . . . . . . . . . . . . 12
7.2 Enforcement . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
7.3 Third Party Claims. . . . . . . . . . . . . . . . . . . . . . . . . 13
7.4 Notice. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
ARTICLE 8 - CONFIDENTIALITY
8.1 Confidentiality . . . . . . . . . . . . . . . . . . . . . . . . . . 14
8.2 This Agreement. . . . . . . . . . . . . . . . . . . . . . . . . . . 15
8.3 Authorized Disclosure . . . . . . . . . . . . . . . . . . . . . . . 15
ARTICLE 9 - INDEMNIFICATION
9.1 Indemnification by Amgen. . . . . . . . . . . . . . . . . . . . . . 15
9.2 Indemnification by Progenitor . . . . . . . . . . . . . . . . . . . 16
9.3 Indemnification Procedure . . . . . . . . . . . . . . . . . . . . . 16
ARTICLE 10 - TERMINATION
10.1 Term. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
10.2 Discontinuation of Development. . . . . . . . . . . . . . . . . . . 16
10.3 Termination of Licenses . . . . . . . . . . . . . . . . . . . . . . 16
10.4 Termination for Default . . . . . . . . . . . . . . . . . . . . . . 16
ii
10.5 Insolvency or Bankruptcy. . . . . . . . . . . . . . . . . . . . . . 17
10.6 Accrued Rights, Surviving Obligations . . . . . . . . . . . . . . . 18
ARTICLE 11 - MISCELLANEOUS PROVISIONS
11.1 Assignment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
11.2 Further Actions . . . . . . . . . . . . . . . . . . . . . . . . . . 18
11.3 Force Majeure . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
11.4 Public Announcements. . . . . . . . . . . . . . . . . . . . . . . . 18
11.5 Notices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
11.6 Amendment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
11.7 Waiver. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
11.8 Counterparts. . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
11.9 Descriptive Headings. . . . . . . . . . . . . . . . . . . . . . . . 19
11.10 Governing Law . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
11.11 Severability. . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
11.12 Entire Agreement of the Parties . . . . . . . . . . . . . . . . . . 20
11.13 Dispute Resolution. . . . . . . . . . . . . . . . . . . . . . . . . 20
11.14 Independent Contractors . . . . . . . . . . . . . . . . . . . . . . 20
11.15 Use of Name . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
11.16 Damages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
EXHIBITS
Exhibit A Progenitor Receptor Patents
iii
LICENSE AGREEMENT
LICENSE AGREEMENT (this "Agreement") dated December 31, 1996 by and
between Progenitor, Inc., a Delaware corporation with principal offices located
at 0000 Xxxxxxxx Xxxx, Xxxxxxxx, Xxxx 00000 ("Progenitor") and Amgen Inc., a
Delaware corporation with principal offices located at Amgen Center, 0000
XxXxxxxxxxx Xxxxx, Xxxxxxxx Xxxx, Xxxxxxxxxx 00000 ("Amgen").
W I T N E S S E T H:
WHEREAS, Progenitor has filed certain patent applications relating to the
leptin receptor including patent applications describing the receptor itself,
antibody to the receptor and methods and uses relating thereto.
WHEREAS, Amgen is engaged in the research, development and
commercialization of human pharmaceutical products.
WHEREAS, Progenitor has agreed to license to Amgen the Progenitor leptin
receptor patent applications and patents issuing therefrom for human
pharmaceutical uses under the terms and conditions set forth herein.
NOW THEREFORE, in consideration of the foregoing and the covenants and
promises contained in this Agreement, the parties agree as follows:
ARTICLE 1
DEFINITIONS
1.1 "ACTIVE COMPONENT" shall mean any proprietary substance or device (other
than a Product) which performs an identifiable therapeutic, prophylactic,
diagnostic or delivery function in combination with a Product.
1.2 "AFFILIATE" shall mean a Person or entity that, directly or indirectly,
through one or more intermediates, controls, is controlled by, or is under
common control with the Person or entity specified. For the purposes of this
definition, control shall mean the direct or indirect ownership of at least
fifty percent (50%) of (i) the stock shares entitled to vote for the election of
directors or (ii) ownership interest.
1.3 "AGREEMENT" shall mean this Agreement.
1.4 "COMBINED PRODUCT" shall mean any product made, used or sold by or on
behalf of Amgen, its Affiliates and/or its sublicensees which consists of a
Product in combination with one or more Active Components.
1
1.5 "CONFIDENTIAL INFORMATION" shall mean information, which, if written, is
marked confidential by the disclosing Party or, if oral, is reduced to writing
and marked confidential by the disclosing Party, within thirty (30) days of the
oral disclosure.
1.6 "CONTROLS" or "CONTROLLED" shall mean possession of the ability to grant
licenses or sublicenses without violating the terms of any agreement or other
arrangement with, or the rights of, any Third Party.
1.7 "DEFAULT" shall mean with respect to either Party (i) that any
representation or warranty of such Party set forth herein shall have been untrue
in any material respect when made and/or (ii) such Party shall have failed to
perform any material obligation set forth herein within sixty (60) days after
receipt of written notice from the other Party specifying in detail the material
obligation which has not been performed and requesting that the failure to
perform be remedied within sixty (60) days.
1.8 "EFFECTIVE DATE" shall mean the date first written above.
1.9 "FDA" shall mean the Federal Food and Drug Administration of the United
States Department of Health and Human Services and successor agencies.
1.10 "FIELD OF USE" shall mean all human therapeutic, prophylactic and
diagnostic uses of Licensed Products. Without limiting the foregoing, the Field
of Use will specifically include all human therapeutic, diagnostic and
prophylactic uses of both proteins and DNAs encoding Licensed Products.
1.11 "FIRST COMMERCIAL SALE" shall mean the initial transfer of a Licensed
Product to a Third Party in exchange for cash or some equivalent to which value
can be assigned for purposes of determining Net Sales.
1.12 "FORCE MAJEURE" shall mean any occurrence beyond the reasonable control
of a Party that prevents or substantially interferes with the performance by the
Party of any of its obligations hereunder, if such occurs by reason of any act
of God, flood, fire, explosion, breakdown of plant, earthquake, strike, lockout,
labor dispute, casualty or accident, or war, revolution, civil commotion, acts
of public enemies, blockage or embargo, or any injunction, law order,
proclamation, regulation, ordinance, demand or requirement of any government or
of any subdivision, authority or representative or any such government,
inability to procure or use materials, labor, equipment, transportation, or
energy sufficient to meet manufacturing needs without the necessity of
allocation, or any other cause whatsoever, whether similar or dissimilar to
those above enumerated, beyond the reasonable control of such Party, if and only
if the Party affected shall have used reasonable efforts to avoid such
occurrence and to remedy it promptly if it shall have occurred.
1.13 "GAAP" shall mean United States generally accepted accounting principles
2
consistently applied.
1.14 "IND" shall mean an Investigational New Drug application filed with the
FDA.
1.15 "LICENSED PATENTS" shall mean the Progenitor Receptor Patents and
Progenitor Ancillary Patents.
1.16 "LICENSED PRODUCT(S)" shall mean Products and Combined Products.
1.17 "NET SALES" shall mean all revenues recognized in accordance with GAAP
from the sale or other disposition of a Licensed Product by Amgen, an Affiliate
or a sublicensee of Amgen to Third Parties, less returns and allowances
(actually paid or allowed, including, but not limited to, prompt payment and
volume discounts, chargebacks from wholesalers and other allowances granted to
customers or wholesalers of products, whether in cash or trade), freight,
shipping, packing, freight and shipping insurance, rebates, and sales and other
taxes based on sales prices when included in gross sales, but not including
taxes when assessed on income derived from such sales.
1.18 "NEW PRODUCT" shall mean a Product (i) which requires a Phase III
Licensing Trial in the United States, United Kingdom, France, Italy, Germany or
Japan in order to obtain marketing approval, (ii) which is chemically distinct
from all other Products which have been approved for marketing in the United
States, United Kingdom, France, Italy, Germany and Japan, (iii) which has a
different mode of action or biological activity from all other Products which
have been approved for marketing in the United States, United Kingdom, France,
Italy, Germany and Japan, and (iv) which is being developed for an indication
for which no other Product is approved for marketing in the United States,
United Kingdom, France, Italy, Germany or Japan. A Combined Product will
contain a New Product only if the Product component of the Combined Product
meets the definition of New Product set forth in this Section 1.18.
1.19 "PARTY" shall mean Amgen or Progenitor, as the case may be, and "PARTIES"
shall mean Amgen and Progenitor collectively.
1.20 "PATENT RIGHT" shall mean patent applications, patents issuing thereon
and any extensions or restorations by existing or future extension or
restoration mechanisms, including without limitation Supplementary Protection
Certificates or the equivalent thereof, renewals, continuations, continuations-
in-part, divisions, patents-of-addition, and/or reissues of any patent.
1.21 "PERSON" shall mean an individual, a partnership, a joint venture, a
corporation, a trust, an estate, an unincorporated organization, or any other
entity, or a government or any department or agency thereof.
1.22 "PHASE III LICENSING TRIAL" shall mean a clinical trial which, if the
defined
3
end-points are met, is intended by Amgen as of the start of such trial to be a
pivotal clinical trial that would constitute sufficient basis for receipt of
marketing approval in the United States, United Kingdom, France, Germany, Italy
or Japan, as the case may be.
1.23 "PRODUCT" shall mean a Patented Product and/or a Patent Pending Product
as defined in Sections 5.4(a) and (b), respectively.
1.24 "PROGENITOR ANCILLARY PATENTS" shall mean any and all Patent Rights owned
or Controlled by Progenitor during the term of this Agreement which are
necessary or useful to make, use, sell, offer for sale or import Licensed
Products. Notwithstanding the foregoing, Progenitor Ancillary Patents will not
include any Patent Rights owned or Controlled by Progenitor that are directed
solely to uses of leptin protein.
1.25 "PROGENITOR RECEPTOR PATENTS" shall mean the Patent Rights owned or
Controlled by Progenitor relating to the leptin receptor and antibodies to the
leptin receptor. The Progenitor Receptor Patents are listed on Exhibit A
hereto.
1.26 "ROYALTIES" shall mean those royalties payable by Amgen to Progenitor
pursuant to Article 5 of this Agreement.
1.27 "THIRD PARTY" shall mean any Person other than Progenitor and Amgen.
1.28 "THIRD PARTY ROYALTIES" shall mean royalties payable by Amgen, an
Affiliate or sublicensee of Amgen to a Third Party (or multiple Third Parties)
to make, use, sell, offer to sell or import Licensed Products.
ARTICLE 2
REPRESENTATIONS AND WARRANTIES
2.1 REPRESENTATIONS AND WARRANTIES OF PROGENITOR.
(a) CORPORATE POWER. As of the Effective Date, Progenitor is duly
organized and validly existing under the laws of Delaware and has full corporate
power and authority to enter into this Agreement and to carry out the provisions
hereof.
(b) DUE AUTHORIZATION. As of the Effective Date, Progenitor is duly
authorized to execute and deliver this Agreement and to perform its obligations
hereunder. The Person executing this Agreement on Progenitor's behalf has been
duly authorized to do so by all requisite corporate action.
(c) BINDING AGREEMENT. This Agreement is a legal and valid obligation
binding upon Progenitor and enforceable in accordance with its terms. As of the
4
Effective Date, the execution, delivery and performance of this Agreement by
Progenitor does not conflict with any agreement, instrument or understanding,
oral or written, to which it is a party or by which it may be bound, nor violate
any material law or regulation of any court, governmental body or administrative
or other agency having jurisdiction over it.
(d) GRANT OF RIGHTS. Progenitor has not, and will not during the term of
this Agreement, grant any right to any Third Party which would conflict with the
rights granted to Amgen hereunder.
(e) VALIDITY. As of the Effective Date, Progenitor is aware of no action,
suit or inquiry or investigation instituted by any United States federal or
state governmental agency which questions or threatens the validity of this
Agreement or the Progenitor Receptor Patents.
(f) PROGENITOR RECEPTOR PATENTS. As of the Effective Date, the Patent
Rights listed on Exhibit A hereto include all Patents Rights owned or Controlled
by Progenitor which claim or describe the leptin receptor and/or antibodies to
the leptin receptor.
2.2 REPRESENTATIONS AND WARRANTIES OF AMGEN.
(a) CORPORATE POWER. As of the Effective Date, Amgen is duly organized
and validly existing under the laws of Delaware and has full corporate power and
authority to enter into this Agreement and carry out the provisions hereof.
(b) DUE AUTHORIZATION. As of the Effective Date, Amgen is duly authorized
to execute and deliver this Agreement and to perform its obligations hereunder.
The Person executing this Agreement on Amgen's behalf has been duly authorized
to do so by all requisite corporate action.
(c) BINDING AGREEMENT. This Agreement is a legal and valid obligation
binding upon Amgen, and enforceable in accordance with its terms. As of the
Effective Date, the execution, delivery and performance of this Agreement by
Amgen does not conflict with any agreement, instrument or understanding, oral or
written, to which it is a party or by which it may be bound, nor violate any
material law or regulation of any court, governmental body or administrative or
other agency having jurisdiction over it.
(d) VALIDITY. As of the Effective Date, Amgen is aware of no action, suit
or inquiry or investigation instituted by any United States federal or state
governmental agency which questions or threatens the validity of this Agreement.
ARTICLE 3
LICENSE GRANT
3.1 TECHNOLOGY OWNERSHIP. Progenitor shall retain sole right and title,
5
subject only to the licenses granted to Amgen in Section 3.2, to the Licensed
Patents.
3.2 LICENSE GRANT.
(a) PROGENITOR RECEPTOR PATENTS. Subject to Section 3.3, Progenitor
hereby grants to Amgen and its Affiliates an exclusive worldwide license, with
the right to grant sublicenses, under the Progenitor Receptor Patents to make,
use, sell, offer for sale and import Licensed Products in the Field of Use.
(b) PROGENITOR ANCILLARY PATENTS. Progenitor hereby grants to Amgen and
its Affiliates a non-exclusive worldwide license, with the right to grant
sublicenses, under the Progenitor Ancillary Patents to make, use, sell, offer
for sale and import Licensed Products in the Field of Use.
(c) SUBLICENSES. Amgen will provide Progenitor with copies of all
sublicense agreements entered into by Amgen and/or its Affiliates which grant
sublicenses under the Licensed Patents ("Sublicense Agreements"). Amgen may
redact or delete the provisions in each Sublicense Agreement which, in Amgen's
judgment, disclose information which is confidential or proprietary to Amgen
and/or its Affiliates. Amgen will provide Progenitor with copies of each
Sublicense Agreement within sixty (60) days after the execution date of such
Sublicense Agreement.
3.3 RETAINED RIGHTS.
(a) EXCLUSIVE RIGHTS. Progenitor and its Affiliates will retain an
exclusive right, with the right to grant licenses, under the Progenitor Receptor
Patents to make, use, sell, offer for sale and import Licensed Products for the
following uses (i) any ex vivo uses of Licensed Products for ligand and small
molecule drug screening, (ii) any ex vivo uses of Licensed Products for cell
sorting, (iii) any anti-sense uses of Licensed Products for human therapeutic,
prophylactic and/or diagnostic applications, and (iv) any in vivo human
therapeutic, prophylactic and/or diagnostic applications of antibodies to the
leptin receptor (collectively, the "Progenitor Retained Rights").
(b) NON-EXCLUSIVE RIGHTS. Progenitor and its Affiliates shall retain (i)
a non-exclusive right, with the right to grant licenses, to make, use, sell,
offer for sale and import Licensed Products for human diagnostic uses, the
exercise of such license to be limited to use only to the extent necessary for
Progenitor to develop and commercialize products under the Progenitor Retained
Rights, and (ii) a non-exclusive right, with no right to grant licenses, under
the Progenitor Receptor Patents in the Field of Use for internal research and
development purposes only.
6
ARTICLE 4
DEVELOPMENT AND COMMERCIALIZATION
4.1 DEVELOPMENT. Amgen, in its sole discretion, will make all decisions
relating to the development of Licensed Products including, but not limited to,
all decisions relating to the research, pre-clinical development and clinical
development of Licensed Products.
4.2 COMMERCIALIZATION. Amgen, in its sole discretion, will make all decisions
relating to the commercialization of Licensed Products including, but not
limited to, all decisions relating to the promotion, advertising, marketing and
pricing of Licensed Products.
4.3 ANNUAL STATEMENT. On an annual basis, for so long as Amgen is continuing
development and commercialization activities with respect to Licensed Products,
Amgen will provide Progenitor with a written statement confirming that such
activities are on-going (the "Annual Statement"). The Annual Statement will be
limited to a recitation by Amgen that Amgen is continuing development and
commercialization activities with respect to Licensed Products. Under no
circumstances will Amgen be obligated to provide Progenitor with reports
describing Amgen's progress in development of Licensed Products, describe in any
way the status of any Licensed Product development programs or provide any data
collected in the conduct of Amgen's development programs for Licensed Products
to Progenitor.
ARTICLE 5
CONSIDERATION
5.1 LICENSE FEE AND EQUITY PURCHASES.
(a) FEE. In consideration for the licenses to the Licensed Patents
granted by Progenitor to Amgen and its Affiliates herein, on the business day
immediately following the Effective Date, Amgen shall pay to Progenitor a
license fee equal to five hundred thousand dollars ($500,000).
(b) EQUITY PURCHASE. Amgen and Progenitor have entered into a Stock
Purchase Agreement of even date herewith (the "Stock Purchase Agreement")
contemplating an investment by Amgen in Progenitor in the amount of five million
five hundred thousand dollars ($5,500,000) by means of the purchase of Common
Stock.
5.2 LICENSE MAINTENANCE FEE. If, on or before the [***] of the
Effective Date, Amgen shall not have filed an IND or initiated human clinical
trials with respect to at least one Licensed Product, Amgen will, within thirty
(30) days
7
after the [***] of the Effective Date, pay to Progenitor a one-time
license maintenance fee equal to [***] .
5.3 MILESTONES. In consideration for the licenses to the Licensed Patents
granted by Progenitor to Amgen and its Affiliates herein, within thirty (30)
days after the first occurrence of each of the following events, Amgen will make
the following milestone payments ("Milestone Payments") to Progenitor:
[* * *]
5.4 ROYALTIES.
(a) PATENTED PRODUCTS. Amgen will pay to Progenitor a Royalty on
cumulative annual worldwide Net Sales by Amgen, its Affiliates and sublicensees
of products, the making, using, selling or importing of which would, but for the
8
licenses to the Licensed Patents granted to Amgen by Progenitor herein, infringe
one or more valid, issued claims included within the Licensed Receptor Patents
in the country of sale ("Patented Products") as set forth below.
- Net Sales of less than or equal to [***][***] of Net Sales
- Net Sales greater than [***][***] of Net Sales
(b) PATENT PENDING PRODUCTS. Amgen will pay to Progenitor a Royalty on
cumulative annual worldwide Net Sales by Amgen, its Affiliates and sublicensees
of products the making, using, selling or importing of which would, but for the
licenses to the Licensed Patents granted to Amgen by Progenitor herein and
assuming such pending claims were to be validly issued, infringe one or more
valid, issued claims included within the Licensed Receptor Patents in the
country of sale ("Patent Pending Products") as set forth below.
- Net Sales of less than or equal to [***][***] of Net Sales
- Net Sales greater than [***][***] of Net Sales
(c) COMBINED PRODUCTS. Amgen will pay to Progenitor a Royalty on
cumulative annual worldwide Net Sales by Amgen, its Affiliates and sublicensees
of Combined Products incorporating Patented Products or Patent Pending Products
as set forth below.
A. In the event each of the Active Components and the Product are
sold separately, the Royalty on sales of Combined Products shall be
equal to [***]
- [***]
- [***]
B. In the event one or more of the components of a Combined Product
are not sold separately, the Royalty shall be equal to [***]
- [***]
9
[***]
- [***]
(d) PRODUCT BY PRODUCT. Royalties shall be payable pursuant to this
Section 5.4 on a Licensed Product by Licensed Product basis, and shall be
imposed only once with respect to any sale of the same unit of Licensed Product.
(e) TERMINATION. Amgen's obligation to pay Royalties to Progenitor on
Patented Products will expire on a Licensed Product by Licensed Product and
country by country basis upon the expiration of the last to expire of the
Licensed Receptor Patents claiming a Licensed Product in a given country.
Amgen's obligation to pay Royalties to Progenitor on Patent Pending Products
will expire on a Licensed Product by Licensed Product and country by country
basis upon the fifth anniversary of the First Commercial Sale of the Licensed
Product in a given country.
5.5 CREDITS AGAINST ROYALTIES AND MILESTONE PAYMENTS.
(a) THIRD PARTY ROYALTY REDUCTION. In the event Amgen shall be obligated
to pay a Third Party Royalty on sales of a Licensed Product, [***]
of such royalty actually paid shall be creditable by Amgen against Royalties
payable to Progenitor on sales of that Licensed Product.
(b) LICENSE MAINTENANCE FEE. In the event Amgen shall pay to Progenitor a
license maintenance fee in accordance with Section 5.2, that fee shall be
creditable against Milestone Payments thereafter payable by Amgen to Progenitor
hereunder.
(c) PATENT EXPENSES. Amgen shall be entitled to credit all costs,
expenses, fees, settlements and the like actually paid by Amgen in the
enforcement and defense of the Licensed Receptor Patents as set forth in Article
7 against Royalties and Milestone Payments payable to Progenitor hereunder.
(d) LIMITATION. In no event will Amgen reduce any Royalty or
Milestone Payment to Progenitor hereunder by more than [***] by reason of the
credits provided for in this Section 5.5.
5.6 PAYMENT OF ROYALTIES.
(a) STATEMENTS. Amgen shall deliver to Progenitor within sixty (60) days
after the end of each calendar quarter, a statement setting forth the Net Sales
of Licensed Products during the previous quarter and the Royalty due hereunder.
The statement shall be accompanied by a remittance of the Royalty due for such
10
quarter. Net Sales and Royalty computations contained in any such statement
shall be certified by Amgen as accurate to the best of its ability consistent
with Amgen standard practices in performing such computations.
(b) CURRENCY. If Net Sales are in a currency other than United States
Dollars, the Net Sales for the purpose of calculating payments hereunder shall
be determined in the applicable foreign currency and then converted into its
equivalent in United States Dollars at the average rate of exchange for buying
funds as published by the Wall Street Journal for the corresponding calendar
quarter.
(c) LEGAL RESTRICTIONS. If at any time legal restrictions prevent the
prompt remittance by Amgen of all or any part of Royalties on Net Sales of
Licensed Products in any country, Amgen shall have the right and option to make
such payment by depositing the amount thereof in local currency to an account in
the name of Progenitor in a bank or other depository in such country. Amgen
will consult with Progenitor and promptly notify Progenitor of any such
arrangements.
(d) TAXES. All taxes levied on account of Royalties accruing under this
Agreement shall be paid by Progenitor. If laws or regulations require
withholding of taxes from any payment to Progenitor, the taxes will be deducted
by Amgen from remittable Royalty to Progenitor and will be paid by Amgen to the
proper taxing authority. Amgen will furnish Progenitor with the original copies
of all official receipts for such taxes. In the event of any such withholding,
the Parties agree to confer regarding other measures to minimize such
withholding.
ARTICLE 6
RECORDS; AUDIT
6.1 RECORD RETENTION. Amgen shall keep complete and accurate records in
sufficient detail to permit Progenitor to confirm the accuracy of calculations
of all payments hereunder. Such records shall be retained by Amgen for no less
than a four (4) year period following the year in which any such payments were
made hereunder.
6.2 ROYALTY AUDIT. Once per calendar year, Progenitor shall have the option to
engage at its own expense, an independent certified public accountant reasonably
acceptable to Amgen, to examine, in confidence, such Amgen records as may be
necessary to determine, with respect to any calendar year, the correctness of
any payment of Royalties hereunder. The report of such accountant shall be
limited to a certificate verifying any report made or payment submitted by Amgen
during such period but may include, in the event the accountant shall be unable
to verify the correctness of any such payment, information relating to why such
payment is unverifiable. All information contained in any such certificate
shall be deemed to be Amgen Confidential Information hereunder. If any audit
performed under this
11
Section 6.2 shall indicate that any payment due hereunder was underpaid,
Amgen shall pay to Progenitor the amount of any underpayment promptly. If
any audit performed under this Section 6.2 shall indicate that any payment
hereunder was in error to Progenitor's detriment by more than [***], Amgen
shall pay the cost of the audit.
6.3 SURVIVAL. This Article 6 shall survive any termination of this Agreement
for a period of four (4) years.
ARTICLE 7
PATENTS
7.1 PATENT PROSECUTION.
(a) COUNSEL. During the term of this Agreement, Progenitor will retain
outside counsel, reasonably acceptable to Amgen, to prosecute and maintain the
Progenitor Receptor Patents in the major market countries. Progenitor will keep
Amgen fully informed on the progress and status of prosecution of the Progenitor
Receptor Patents.
(b) CORRESPONDENCE AND FILINGS. Progenitor will provide Amgen with copies
of all Progenitor filings with and correspondence submitted to the United States
Patent and Trademark Office and comparable foreign offices which relate to the
Progenitor Receptor Patents and will provide Amgen with a reasonable opportunity
to comment on all such correspondence and filings prior to submission.
Progenitor will consider Amgen's comments relating to such filings and
correspondence and, where appropriate, incorporate such comments, but the final
decision with respect to content of Progenitor's filings and correspondence
shall be at Progenitor's option and discretion. Upon receipt by Progenitor,
Progenitor will promptly provide Amgen with copies of all correspondence from
the United States Patent and Trademark Office and comparable foreign offices
which relate to the Progenitor Receptor Patents.
(c) EXPENSES. All expenses in connection with prosecution and maintenance
of the Licensed Patents will be borne by Progenitor.
7.2 ENFORCEMENT.
(a) NOTIFICATION OF INFRINGEMENT. If either Party learns of an
infringement by a Third Party of a Patent Right included in the Licensed Patents
in the Field of Use, such Party shall promptly notify the other Party and shall
provide such other Party with available evidence of such infringement.
(b) ENFORCEMENT BY PROGENITOR. Progenitor shall have the first right to
elect to enforce the Progenitor Receptor Patents in the Field of Use against
Third
12
Parties worldwide. In the event Progenitor shall so elect, Progenitor shall
determine the worldwide strategy and Amgen shall assist and cooperate with
Progenitor in any such enforcement. Progenitor shall consult with Amgen and
keep Amgen regularly advised of Progenitor's strategies, plans, progress and
results of any such enforcement action. Progenitor shall bear all associated
costs and expenses (including attorneys' fees). In the event damages or
recoveries shall be awarded in such action, such amounts shall be applied first
to reimburse Progenitor for any costs incurred in bringing such action.
Remaining amounts will be paid to Amgen and treated as Net Sales in the year in
which such amounts are received by Amgen for purposes of determination of
Royalties payable by Amgen to Progenitor.
(c) ENFORCEMENT BY AMGEN. In the event Progenitor elects not to enforce
the Progenitor Receptor Patents against any Third Party in the Field of Use,
Amgen shall have the right, but not the obligation, to elect to enforce the
Licensed Receptor Patents against such Third Party worldwide in the Field of
Use. In the event Amgen shall so elect, Amgen shall determine the worldwide
strategy and Progenitor shall assist and cooperate with Amgen in any such
enforcement. Amgen shall consult with Progenitor and keep Progenitor regularly
advised of Amgen's strategies, plans, progress and results of any such
enforcement action. Amgen shall bear all associated costs and expenses
(including attorneys' fees). In the event damages or recoveries shall be
awarded in such action, such amounts shall be applied first to reimburse Amgen
for any costs incurred in bringing such action. Remaining amounts will be
retained by Amgen and treated as Net Sales in the year in which such amounts are
received by Amgen for purposes of determination of Royalties payable by Amgen to
Progenitor.
7.3 THIRD PARTY CLAIMS.
(a) DEFENSE BY AMGEN. Amgen (i) may, but shall not be obligated to, elect
to defend the Licensed Receptor Patents against Third Party claims that the
Licensed Receptor Patents in the Field of Use are invalid or unenforceable and
(ii) will defend any action naming Amgen or Amgen and Progenitor and claiming
the infringement of any Third Party Patent Right through the making, using or
selling of Licensed Products. Amgen shall consult with Progenitor and keep
Progenitor regularly advised of Amgen's strategies, plans, progress and results
of any such defense. Progenitor may, at its expense, select counsel of its
choice to assist Amgen's counsel in connection with such defense and shall
assist and cooperate with Amgen in any such defense. Amgen shall bear all
associated costs and expenses (including attorneys' fees) and pay all damages
and settlement amounts, PROVIDED, HOWEVER, that all costs and expenses actually
incurred by Amgen in connection with Amgen's defense of the Licensed Patents and
all damages and settlements actually paid by Amgen as a result thereof shall be
creditable against Royalties and Milestone Payments payable by Amgen to
Progenitor.
(b) DEFENSE BY PROGENITOR. In the event Amgen does not elect to defend
the Progenitor Receptor Patents as set forth in (a) above, Progenitor shall
defend the Progenitor Receptor Patents and shall bear all associated costs and
expenses
13
(including attorneys' fees) and pay all damages and settlement amounts.
Progenitor shall consult with Amgen and keep Amgen regularly advised of
Progenitor's strategies, plans, progress and results of any such defense.
(c) ACTIONS TO THE DETRIMENT OF LICENSED PATENTS. (i) Amgen will not
enter into any settlement action or agree to any settlement arrangement that may
negatively impact the Licensed Patents without the express prior written consent
of Progenitor, such consent not to be unreasonably withheld. A settlement
action or arrangement which provides for the payment of royalties to a Third
Party but does not specifically address the validity or enforceability of the
Licensed Patents shall not be deemed to negatively impact the Licensed Patents
and may be entered into by Amgen at Amgen's discretion. (ii) Progenitor will
not enter into any settlement action or agree to any settlement that may
negatively impact the Licensed Patents in the Field of Use without the express
prior written consent of Amgen, such consent not to be unreasonably withheld.
7.4 NOTICE. Each Party will promptly notify the other upon becoming aware of
(i) any Third Party claim or action against Progenitor and/or Amgen for
infringement of Third Party Patent Rights through the making, using, selling or
importing of Licensed Products, (ii) any Third Party claim or action against
Progenitor for infringement of Third Party Patent Rights through the making,
using, selling or importing of products under the Licensed Patents, or (iii) any
Third Party infringement of the Licensed Patents.
ARTICLE 8
CONFIDENTIALITY
8.1 CONFIDENTIALITY. Except to the extent expressly authorized by this
Agreement or otherwise agreed in writing by the Parties, the Parties agree to
keep confidential and not publish or otherwise disclose or use for any purpose,
other than as provided for this Agreement, any Confidential Information except
to the extent that it can be established by the receiving Party by competent
proof that such Confidential Information:
(a) was already known to the receiving Party, other than under an
obligation of confidentiality, at the time of disclosure by the other Party;
(b) was generally available to the public or otherwise part of the public
domain at the time of its disclosure to the receiving Party;
(c) became generally available to the public or otherwise part of the
public domain after its disclosure and other than through any act or omission of
the receiving Party in breach of this Agreement;
14
(d) was disclosed to the receiving Party, other than under an obligation
of confidentiality to a Third Party, by a Third Party who had no obligation to
the disclosing Party not to disclose such information to others; or
(e) was independently discovered or developed by the receiving Party
without the use of Confidential Information belonging to the disclosing Party.
8.2 THIS AGREEMENT. The Parties agree that the material terms of the Agreement
shall be considered Confidential Information of both Parties. The Parties will
consult with one another and agree on the provisions of the Agreement to be
redacted in any filings made by the Parties with the Securities and Exchange
Commission or as otherwise required by law or regulation. Notwithstanding the
foregoing, each Party shall have the right to disclose in confidence the
material terms of the Agreement to parties retained by such Party to perform
legal, accounting or similar services and who have a need to know such terms in
order to provide such services.
8.3 AUTHORIZED DISCLOSURE. Each Party may disclose Confidential Information
belonging to the other Party to the extent such disclosure is reasonably
necessary in the following:
(a) filing or prosecuting the Licensed Patents;
(b) regulatory filings;
(c) prosecuting or defending litigation;
(d) complying with applicable regulations of governmental authorities;
(e) conducting pre-clinical or clinical trials of Licensed Products; and
(f) medical education, marketing and sales of Licensed Products.
Notwithstanding the foregoing, in the event a Party is required to make a
disclosure of the other Party's Confidential Information pursuant to this
Section 8.3, it will, except where impracticable, give reasonable advance
notice to the other Party of such disclosure and use best efforts to secure
confidential treatment of such information. In any event, the Parties agree to
take all reasonable action to avoid disclosure of Confidential Information
hereunder.
ARTICLE 9
INDEMNIFICATION
9.1 INDEMNIFICATION BY AMGEN. Amgen shall indemnify and hold Progenitor
harmless from any claims of any nature, other than claims by Third Parties
relating
15
to patent infringement, arising out of the research, development, marketing
and/or sale of Licensed Products by, on behalf of, or under the authority of
Amgen. Notwithstanding the foregoing, Progenitor shall not be entitled to
indemnification under this Section 9.1 against any liability, damage, cost
(including reasonable attorneys' fees) or expense arising out of Progenitor's
negligence or misconduct.
9.2 INDEMNIFICATION BY PROGENITOR. Progenitor shall indemnify and hold Amgen
harmless from claims of any nature arising out of the making, using, selling or
importing of products claimed in the Licensed Patents by, on behalf of, or under
the authority of Progenitor. Notwithstanding the foregoing, Amgen shall not be
entitled to indemnification under this Section 9.2 against any liability,
damage, cost (including reasonable attorneys' fees) or expense arising out of
Amgen's negligence or misconduct.
9.3 INDEMNIFICATION PROCEDURE. In the event that either Party shall receive
notice of a claim for which indemnification may be sought under Section 9.1 or
9.2 above, such Party shall promptly inform the indemnifying Party and the
indemnifying Party shall decide how to respond to the claim and how to handle
the claim in an efficient manner.
ARTICLE 10
TERMINATION
10.1 TERM. The Agreement will terminate upon the expiration of the last to
expire of the Licensed Patents worldwide.
10.2 DISCONTINUATION OF DEVELOPMENT. In the event Amgen shall at any time
elect to discontinue all development and commercialization activities relating
to Licensed Products, Amgen will notify Progenitor in writing of such election
and upon Progenitor's receipt of such notification, this Agreement will
terminate and all licenses under the Licensed Patents granted to Amgen and its
Affiliates hereunder will revert to Progenitor.
10.3 TERMINATION OF LICENSES. Amgen shall have the right, at any time, upon
[***], to terminate, in whole or in part, any of the licenses under the
Licensed Patents granted to Amgen and its Affiliates hereunder. Upon Amgen's
termination of all licenses under the Licensed Patents granted to Amgen and
its Affiliates hereunder all such licenses will revert to Progenitor and this
Agreement will terminate.
10.4 TERMINATION FOR DEFAULT.
(a) AMGEN. Upon the Default by Amgen under this Agreement, Progenitor
16
may terminate this Agreement by written notice to Amgen and upon Amgen's receipt
of such notice, all licenses under the Licensed Patents granted to Amgen and its
Affiliates hereunder will revert to Progenitor.
(b) PROGENITOR. Upon the Default by Progenitor under this Agreement,
Amgen shall be relieved of its obligations to pay Royalties and Milestone
Payments to Progenitor hereunder for any events occurring during the period in
which the Default shall remain uncured.
10.5 INSOLVENCY OR BANKRUPTCY.
(a) INSOLVENT PARTY. Either Party may, in addition to any other remedies
available to it by law or in equity, terminate this Agreement, in whole or in
part, by written notice to the other Party (the "Insolvent Party") in the event
the Insolvent Party shall have become insolvent or bankrupt, or shall have made
an assignment for the benefit of its creditors, or there shall have been
appointed a trustee or receiver of the Insolvent Party or for all or a
substantial part of its property, or any case or proceeding shall have been
commenced or other action taken by or against the Insolvent Party in bankruptcy
or seeking reorganization, liquidation, dissolution, winding-up arrangement,
composition or readjustment of its debts or any other relief under any
bankruptcy, insolvency, reorganization or other similar act or law of any
jurisdiction now or hereafter in effect, or there shall have been issued a
warrant of attachment, execution, distraint or similar process against any
substantial part of the property of the Insolvent Party, and any such event
shall have continued for sixty (60) days undismissed, unbonded and undischarged.
(b) RIGHTS IN BANKRUPTCY. All rights and licenses granted under or
pursuant to this Agreement by Progenitor are, and shall otherwise be deemed to
be, for purposes of Xxxxxxx 000 (x) xx xxx Xxxxxx Xxxxxx Bankruptcy Code,
licenses of rights to "intellectual property" as defined under Section 101 of
the United States Bankruptcy Code. The Parties agree that the Parties, as
licensor and licensee of such rights under this Agreement, shall retain and may
fully exercise all of their rights and elections under the United States
Bankruptcy Code. The Parties further agree that, in the event of the
commencement of a bankruptcy proceeding by or against either Party under the
United States Bankruptcy Code, the Party hereto which is not a Party to such
proceeding shall be entitled to a complete duplicate of (or complete access to,
as appropriate) any such intellectual property and all embodiments of such
intellectual property, and same, if not already in the their possession, shall
be promptly delivered to them (i) upon any such commencement of a bankruptcy
proceeding upon their written request therefor, unless the Party subject to such
proceeding elects to continue to perform all of their obligations under this
Agreement, or (ii) if not delivered under (i) above, upon the rejection of this
Agreement by or on behalf of the Party subject to such proceeding upon written
request therefor by any non-subject Party.
(c) LICENSES UPON BANKRUPTCY. Upon the termination of this Agreement by
Progenitor pursuant to this Section 10.5, all of the Parties' rights and
obligations
17
set forth in this Agreement will terminate and all licenses under the Licensed
Patents granted to Amgen and its Affiliates hereunder will revert to Progenitor.
Upon the termination of this Agreement by Amgen pursuant to this Section 10.5,
(i) Amgen will retain all licenses to the Licensed Patents granted to Amgen and
its Affiliates hereunder, subject to the payment by Amgen to Progenitor of all
fees, Milestone Payments and Royalties as set forth in Article 5, and (ii)
except as set forth in (i) above, all of the Parties' rights and obligations set
forth in this Agreement shall terminate.
10.6 ACCRUED RIGHTS, SURVIVING OBLIGATIONS. Termination, relinquishment or
expiration of this Agreement for any reason shall be without prejudice to any
rights which shall have accrued to the benefit of either Party prior to such
termination, relinquishment or expiration. Such termination, relinquishment or
expiration shall not relieve either Party from obligations accrued under
Articles 8 and 9.
ARTICLE 11
MISCELLANEOUS PROVISIONS
11.1 ASSIGNMENT. Neither this Agreement nor any interest hereunder shall be
assignable by either Party without the prior written consent of the other Party.
This Agreement shall be binding upon the successors and permitted assigns of the
Parties and the name of a Party appearing herein shall be deemed to include the
names of such Party's successors and permitted assigns to the extent necessary
to carry out the intent of this Agreement. Any assignment not in accordance
with this Section 11.1 shall be void.
11.2 FURTHER ACTIONS. Each Party agrees to execute, acknowledge and deliver
such further instruments, and to do all such other acts, as may be necessary or
appropriate in order to carry out the purposes and intent of the Agreement.
11.3 FORCE MAJEURE. Neither Party shall be liable to the other for loss or
damages or shall have any right to terminate this Agreement for any default or
delay attributable to any Force Majeure, if the Party affected shall give prompt
notice of any such cause to the other Party. The Party giving such notice shall
thereupon be excused from such of its obligations hereunder as it is thereby
disabled from performing for so long as it is so disabled, PROVIDED, HOWEVER,
that such affected Party commences and continues to take reasonable and diligent
actions to cure such cause.
11.4 PUBLIC ANNOUNCEMENTS. If either Party desires to, or is required by law
to, make a public announcement concerning this Agreement, the Licensed Patents
and/or Licensed Products, such Party shall give reasonable prior advance notice
of the proposed text of such announcement to the other Party for its prior
review and approval. The Parties agree to make no public announcement regarding
this
18
Agreement other than those required by law. The text of all public
announcements regarding this Agreement shall be mutually agreed by the Parties,
PROVIDED, HOWEVER, that neither Party shall be prohibited from making any
announcements required by law so long as the other Party shall have had an
opportunity to comment on the text of such announcement.
11.5 NOTICES. All notices and other communications hereunder shall be in
writing and shall be deemed given if delivered personally or by facsimile
transmission (receipt verified), telexed, mailed by registered or certified mail
(return receipt requested), postage prepaid, or sent by express courier service,
to the parties at the following addresses (or at such other address for a Party
as shall be specified by like notice, PROVIDED, HOWEVER, that notices of a
change of address shall be effective only upon receipt thereof):
If to Amgen, addressed to:
Amgen Inc.
Amgen Center
0000 XxXxxxxxxxx Xxxxx
Xxxxxxxx Xxxx, Xxxxxxxxxx 00000
Attention: Secretary
With a copy to: Vice President, Product Licensing
Facsimile: (000) 000-0000
If to Progenitor, addressed to:
Progenitor, Inc.
0000 Xxxxxxxx Xxxx
Xxxxxxxx, Xxxx 00000-0000
Attention: Vice President, Corporate Development
With a copy to: Chief Executive Officer
Facsimile: (000) 000-0000
11.6 AMENDMENT. No amendment, modification or supplement of any provision of
this Agreement shall be valid or effective unless made in writing and signed by
a duly authorized officer of each Party.
11.7 WAIVER. No provision of the Agreement shall be waived by any act,
omission or knowledge of any Party or its agents or employees except by an
instrument in writing expressly waiving such provision and signed by a duly
authorized officer of the waiving Party.
11.8 COUNTERPARTS. This Agreement may be executed in any number of
counterparts, each of which need not contain the signature of more than one
Party but all such counterparts taken together shall constitute one and the same
19
agreement.
11.9 DESCRIPTIVE HEADINGS. The descriptive headings of this Agreement are for
convenience only, and shall be of no force or effect in construing or
interpreting any of the provisions of this Agreement.
11.10 GOVERNING LAW. This Agreement shall be governed by and interpreted in
accordance with the substantive laws of the State of California and the Parties
hereby submit to the exclusive jurisdiction of the California courts, both state
and federal.
11.11 SEVERABILITY. Whenever possible, each provision of this Agreement will be
interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Agreement is held to be prohibited by or invalid
under applicable law, such provision will be ineffective only to the extent of
such prohibition or invalidity, without invalidating the remainder of this
Agreement.
11.12 ENTIRE AGREEMENT OF THE PARTIES. This Agreement and the Stock Purchase
Agreement of even date herewith will constitute and contain the complete, final
and exclusive understanding and agreement of the Parties and cancels and
supersedes any and all prior negotiations, correspondence, understandings and
agreements, whether oral or written, between the Parties respecting the subject
matter thereof.
11.13 DISPUTE RESOLUTION. The Parties agree that in the event of a dispute
between them arising from, concerning or in any way relating to this Agreement,
the Parties shall undertake good faith efforts to resolve any such dispute in
good faith. In the event the Parties shall be unable to resolve any such
dispute, the matter shall be referred to the Chief Executive Officer of Amgen
and the Chief Executive Officer of Progenitor for further review and resolution.
If after such efforts, the Parties are unable to resolve such dispute, a Party
may seek any remedy available under applicable law.
11.14 INDEPENDENT CONTRACTORS. The relationship between Amgen and Progenitor
created by this Agreement is one of independent contractors and neither Party
shall have the power or authority to bind or obligate the other except as
expressly set forth in this Agreement.
11.15 USE OF NAME. No right, express or implied, is granted to either Party by
this Agreement to use in any manner any trademark or trade name of the other
Party including the names "Amgen" and "Progenitor" without the prior written
consent of the owning Party.
11.16 DAMAGES. In no event shall either Party be responsible for any
consequential damages incurred by the other Party in connection with this
Agreement, including, without limitation, lost profits or opportunities or
injury to
20
Person or property resulting from the termination of this Agreement.
21
IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of
the date first above written.
AMGEN INC.
/s/ Xxxxxx X. Xxxxxxxx
By: Xxxxxx X. Xxxxxxxx
Title: Senior Vice President,
General Counsel and Secretary
PROGENITOR, INC.
/s/ Xxxxxxxx X. Given
By: Xxxxxxxx X. Given
Title: President and
Chief Executive Officer
22
Exhibit "A"
- [***]
- [***]
- [***]
- [***]
- [***]
- [***]
- [***]
- [***]
- [***]
- [***]
- [***]
- [***]
- [***]
